Lyell Immunopharma LYEL Income Statement (2020-2026)

NASDAQ LYEL
$9.63 -0.11 (-1.13%)
At close: Sep 29, 2026 · 4:00 PM EDT
Reported Financials

Lyell Immunopharma Quarterly Income Statement

Periods 25 quarters
Latest Jun 2026

Lyell Immunopharma reported revenue of $0.00M and net income of -$47.34M for the quarter ended Jun 2026, down 50.0% year over year. This income statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
11.99M6.80M12.27M12.36M12.46M12.48M12.48M12.55M12.59M12.70M12.75M12.80M12.83M14.74M14.76M14.83M19.29M17.09M23.33M23.40M
Revenue & cost
Revenue
2.75M2.82M0.55M35.74M0.00M48.39M0.07M0.03M0.03M0.01M0.00M0.01M0.03M0.01M0.01M0.01M0.01M0.01M0.00M0.00M
Operating items
Research & DevelopmentR&D
31.43M19.29M35.83M43.72M41.61M38.03M44.63M47.47M43.85M46.99M43.17M40.26M39.50M48.67M43.45M34.86M28.17M52.20M36.60M39.52M
Selling, General & AdministrativeSG&A
21.24M31.87M34.42M30.45M26.08M26.35M19.28M19.03M15.51M13.17M13.49M12.26M11.77M14.52M14.05M9.79M10.69M10.62M9.55M9.58M
Other Operating ExpensesOther Opex
0.76M0.80M1.12M1.17M1.25M1.21M1.29M0.57M0.29M0.64M1.09M0.98M0.73M0.51M0.12M-1.06M1.59M1.50M1.90M1.76M
Operating ExpensesOpex
51.92M50.36M69.13M73.00M66.44M63.17M62.62M65.93M59.06M59.52M55.58M51.54M50.54M201.16M57.37M47.15M37.27M127.65M44.26M47.34M
Operating IncomeOp. Inc
-49.16M-47.54M-68.58M-37.26M-66.44M-14.78M-62.56M-65.91M-59.04M-59.51M-55.58M-51.53M-50.51M-201.15M-57.37M-47.14M-37.25M-127.64M-44.26M-47.34M
EBIT
-49.16M-47.54M-68.58M-37.26M-66.44M-14.78M-62.56M-65.91M-59.04M-59.51M-55.58M-51.53M-50.51M-201.15M-57.37M-47.14M-37.25M-127.64M-44.26M-47.34M
Non-operating items
Interest & Investment IncomeInt & Inv Inc
0.27M
Other Non Operating IncomeOther Non Op Inc.
0.02M-0.04M0.04M-0.01M-1.07M2.93M1.10M-0.33M1.58M-0.51M1.09M-0.65M-0.04M4.29M1.31M1.18M-4.86M-15.76M17.91M0.40M
Non Operating IncomeNon Op. Inc.
0.29M-36.17M0.43M0.94M-3.82M6.39M-4.40M2.02M8.19M6.58M-5.09M5.72M5.92M9.21M5.17M4.46M-1.59M-13.08M20.11M2.58M
Net income details
EBT
-48.89M-47.54M-68.58M-37.26M-66.44M-14.78M-62.56M-65.91M-59.04M-59.51M-55.58M-51.53M-50.51M-201.15M-57.37M-47.14M-37.25M-127.64M-44.26M-47.34M
Profit After TaxPAT
-48.89M-47.54M-68.58M-37.26M-66.44M-14.78M-62.56M-65.91M-59.04M-59.51M-55.58M-51.53M-50.51M-201.15M-57.37M-47.14M-37.25M-127.64M-44.26M-47.34M
Income from Continuing OperationsIncome (Continuing)
-48.89M-47.54M-68.58M-37.26M-66.44M-14.78M-62.56M-65.91M-59.04M-59.51M-55.58M-51.53M-50.51M-201.15M-57.37M-47.14M-37.25M-127.64M-44.26M-47.34M
Consolidated Net IncomeConsol Net Inc.
-48.89M-47.54M-68.58M-37.26M-66.44M-14.78M-62.56M-65.91M-59.04M-59.51M-55.58M-51.53M-50.51M-201.15M-57.37M-47.14M-37.25M-127.64M-44.26M-47.34M
Income towards Parent CompanyParent Net Inc
-48.88M-83.71M-68.14M-36.32M-70.25M-8.40M-66.96M-63.89M-50.85M-52.93M-60.67M-45.81M-44.58M-191.94M-52.20M-42.68M-38.85M-140.72M-24.15M-44.76M
Net Income towards Common StockholdersNet Income
-48.88M-83.71M-68.14M-36.32M-70.25M-8.40M-66.96M-63.89M-50.85M-52.93M-60.67M-45.81M-44.58M-191.94M-52.20M-42.68M-38.85M-140.72M-24.15M-44.76M
Additional items
EPS (Basic)
-4.08-12.32-5.58-2.95-5.66-0.68-5.37-5.11-4.05-4.22-4.77-3.59-3.48-14.68-3.54-2.89-2.13-8.23-1.10-1.92
EPS (Diluted)
-4.08-12.32-5.58-2.95-5.66-0.68-5.37-5.11-4.05-4.22-4.77-3.59-3.48-14.68-3.54-2.89-2.13-8.23-1.10-1.92
Shares Outstanding
11.97M6.80M12.21M12.32M12.42M12.35M12.48M12.51M12.57M12.55M12.71M12.77M12.82M13.07M14.75M14.79M18.27M17.09M21.88M23.36M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
11.97M6.80M12.21M12.32M12.42M12.35M12.48M12.51M12.57M12.55M12.71M12.77M12.82M13.07M14.75M14.79M18.27M17.09M21.88M23.36M
EBITDA
-45.07M-42.97M-64.39M-33.09M-61.82M-9.74M-57.53M-60.84M-53.94M-54.45M-50.55M-46.63M-45.83M-196.12M-53.93M-44.01M-34.69M-125.25M-41.93M-45.12M

Lyell Immunopharma Income Statement API

Pull Lyell Immunopharma's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=LYEL&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY